Cyclacel Pharmaceuticals (NASDAQ:CYCC) Releases Quarterly Earnings Results

by · The Markets Daily

Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Free Report) announced its quarterly earnings results on Wednesday. The biotechnology company reported ($0.33) earnings per share for the quarter, Zacks reports. Cyclacel Pharmaceuticals had a negative net margin of 18,150.00% and a negative return on equity of 1,901.11%.

Cyclacel Pharmaceuticals Price Performance

Shares of NASDAQ:CYCC traded down $0.02 during midday trading on Wednesday, reaching $0.25. 295,405 shares of the company’s stock were exchanged, compared to its average volume of 1,203,308. The stock has a market cap of $1.54 million, a price-to-earnings ratio of -0.03 and a beta of 0.28. The firm’s 50 day simple moving average is $0.33 and its two-hundred day simple moving average is $0.50. Cyclacel Pharmaceuticals has a fifty-two week low of $0.23 and a fifty-two week high of $4.00.

Analyst Upgrades and Downgrades

Separately, StockNews.com initiated coverage on shares of Cyclacel Pharmaceuticals in a research note on Monday. They issued a “sell” rating for the company.

Check Out Our Latest Stock Analysis on CYCC

Insider Buying and Selling at Cyclacel Pharmaceuticals

In other news, CEO David E. Lazar sold 194,628,820 shares of the firm’s stock in a transaction on Wednesday, February 26th. The stock was sold at an average price of $0.03, for a total transaction of $5,838,864.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 23.97% of the company’s stock.

About Cyclacel Pharmaceuticals

(Get Free Report)

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.

Recommended Stories